Periventricular Nodular Heterotopia
|
0.410 |
Biomarker
|
disease |
HPO |
|
|
|
PERIVENTRICULAR NODULAR HETEROTOPIA 8
|
0.400 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
Aortic Aneurysm
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Aortic Valve Insufficiency
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Patent ductus arteriosus
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Gastroesophageal reflux disease
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Hernia
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Muscle Spasticity
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Pyloric Stenosis
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Scoliosis, unspecified
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Joint laxity
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Abnormal heart valve morphology
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Thin skin
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Delayed speech and language development
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Seizures, Focal
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Attention deficit hyperactivity disorder
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Delayed myelination
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Bleeding tendency
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Spasticity, CTCAE
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
The CDKN2A tumor-suppressor gene in chromosome band 9p21 encoding CDKN2A (also known as p16, INK4A), a negative regulator of cyclin-dependent kinases, and p14(ARF1), an activator of TP53, is inactivated in many human cancers by point mutations, promoter hypermethylation, or deletions.
|
12696062 |
2003 |
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
The CDKN2A tumor-suppressor locus on chromosome band 9p21, which encodes p16(INK4A), a negative regulator of cyclin-dependent kinases, and p14(ARF1), an activator of TP53, is inactivated in many human cancers by point mutation, promoter hypermethylation, and, often, deletion.
|
15495191 |
2005 |
Mammary Neoplasms
|
0.310 |
AlteredExpression
|
group |
LHGDN |
ADP-ribosylation factor 1 controls the activation of the phosphatidylinositol 3-kinase pathway to regulate epidermal growth factor-dependent growth and migration of breast cancer cells.
|
18990689 |
2008 |
Periventricular Nodular Heterotopia
|
0.410 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the BIG2 Arf1 GEF have been linked to autosomal recessive periventricular heterotopia, a disorder of neuronal migration that leads to severe malformation of the cerebral cortex.
|
19669794 |
2009 |
Tumor Cell Invasion
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
Elevated ARF1 expression was strongly correlated with lymph node metastasis (P = 0.008), serosal invasion (P = 0.046), lymphatic invasion (P = 0.035), and pathological staging (P = 0.010).
|
22348287 |
2012 |
Malignant neoplasm of stomach
|
0.010 |
Biomarker
|
disease |
BEFREE |
These findings collectively support the utility of ARF1 as a novel prognostic marker for gastric cancer and its role in cell invasion.
|
22348287 |
2012 |